Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  Tips voor een nieuwe beleggingsliefde.....

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

Tips voor een nieuwe beleggingsliefde.....

235 Posts
Pagina: «« 1 ... 6 7 8 9 10 ... 12 »» | Laatste | Omlaag ↓
  2. [verwijderd] 18 november 2010 18:57
    Inderdaad, het speert omhoog.
    YTD trouwens +64%.
    Waarschijnlijk is de waarde gebaseerd op de (miljarden?)claim tegen SIGA, die al dan niet in de toekomst tot uitkering gaat komen, mogelijk middels een aandeel in de winst van SIGA's pokkenmedicijn (heb even geen beter woord).

    Dit soort rallies zijn er bij PIP vaker geweest dit jaar.
    Maar als je naar de cijfers van nu kijkt, zijn nieuwe emissies niet uit te sluiten. Immers, met nieuwe verliezen duikt het Eigen Vermogen onder nul.

    Winnen ze de rechtszaak, dan gaan ze winst maken, en is het EV verder niet meer aan erosie onderhevig.
    Het blijft een gokaandeel in mijn ogen.
    En ook die moet je in je porto hebben voor de sjeu.
    Alleen maar Unilever en Kon.Olie is zo saai.

    Maar ik heb ze niet, PIP.
    Mij een beetje te link.
    Ik zou die +20% in 1 week pakken.

    Een artikel van 18 oktober jl:
    PharmAthene also caught a huge boost from last week’s news that the United States is spending up to $2.8 billion to shore up its defenses against biological warfare, according to SIGA Technologies, Inc. (Nasdaq: SIGA), the drugmaker who expects to get a government contract to supply smallpox antiviral drugs.In December 2006, PharmAthene had filed a case against SIGA pursuant to a merger agreement between the companies that was terminated in October 2006. The trial is expected to start on Jan. 3, 2011. Noble Financial Capital Markets analyst Raghuram Selvaraju expects the court case with PharmAthene to be ruled in its favor, with PharmAthene getting a percentage of SIGA’s contract with the government. Roth Capital Partners analyst Joseph Pantginis said the contract has positive implications to PharmAthene that can now identify the exact measure of potential damages.
  4. [verwijderd] 24 november 2010 13:05
    quote:

    wilb52 schreef:

    Ik zoek het totaal niet meer in de Biotech.

    Daar valt misschien best wel wat te verdienen,
    maar er zijn andere sektoren genoeg, met name in de VS

    1 Voorbeeld

    Uranium Resources
    van 50 ct naar 2.50 in slechts maanden (:->D)
    Hij gaat lekker deze maand.
    Met wat van mezelf en beetje van TOPHOUND en een beetje van Wilb52

    PIP: 11 nov. erin voor 3,17 eruit op 3,59

    EDAP: Vorige week maandag erin voor 4,10 dinsdags eruit voor 4,55
    Vanmiddag waarschijnlijk er weer in voor rond de 4,60
    EDAP wacht op goedkeuring HIFU in de USA en in China
    Amerikanen komen naar Europa voor een HIFU- behandeling.
    www.scp.nfk.nl/over_prostaatkanker/sc...
    www.youtube.com/watch?v=qwZzWcPPu58&a...
    www.youtube.com/watch?v=E2oWAt6fpCI&a...

    URRE Met dank aan Wilb52 (URZ doet globaal hetzelfde)
    Gisteren erin voor 2,49 en eruit (Wellicht te vroeg) op 2,81.

    Louis
  5. [verwijderd] 24 november 2010 14:36
    Krijg de PIP

    :->#)

    PharmAthene Announces Full Exercise of Over-Allotment Option
    Last update: 11/24/2010 8:30:00 AM

    ANNAPOLIS, Md., Nov. 24, 2010 /PRNewswire via COMTEX/ -- PharmAthene, Inc., (PIP) a biodefense company developing medical countermeasures against biological and chemical threats, today announced that the 645,000 share over-allotment option granted to the underwriter in conjunction with the registered public offering consummated on November 3, 2010 was exercised in full on November 22, 2010. The closing of the sale of the related shares occurred on November 23, 2010.

    The sale of the over-allotment shares generated net proceeds, before expenses, of approximately $2.1 million, which the Company intends to use for repayment of debt and general corporate purposes. Roth Capital Partners, LLC served as sole underwriter for the offering. Noble Financial Capital Markets served as the Company's financial advisor in connection with the offering. The securities described above were offered by PharmAthene pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission on February 13, 2009.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Copies of the prospectus and the final prospectus supplement may be obtained, when available, at the Securities and Exchange Commission's website at . Copies of the prospectus and the final prospectus supplement may also be obtained from Roth Capital Partners, LLC Equity Capital Markets, 24 Corporate Plaza, Newport Beach, CA 92660, at 800-678-9147 and Rothecm@roth.com.

    About PharmAthene, Inc.

    PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include: SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection Countermeasures for nerve agent poisoning by organophosphate compounds, including nerve gases and pesticides, whose active ingredient is the recombinant enzyme, butyrylcholinesterase (rBChE)
  6. [verwijderd] 24 november 2010 16:39
    Delaware Court Denies SIGA's Motion for Partial Summary Judgment in its Entirety
    Last update: 11/24/2010 10:32:00 AM

    PharmAthene's Breach of Contract Lawsuit Against SIGA Technologies to Proceed to Trial Starting January 3, 2011 ANNAPOLIS, Md., Nov. 24, 2010 /PRNewswire via COMTEX/

    -- PharmAthene, Inc. (PIP) announced today that the Delaware Court of Chancery has issued a ruling denying in full SIGA Technologies' motion for partial summary judgment in PharmAthene's breach of contract lawsuit against SIGA. Trial on all counts in PharmAthene's complaint in this case is set to commence on January 3, 2011. Statement on Cautionary Factors Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements.

    Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, there can be no assurance that the Company will prevail in its lawsuit against SIGA or that even if the court rules in the Company's favor the court will award monetary damages or other remedies adequate to fully compensate the Company for its loses.

    Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at .

    SOURCE PharmAthene, Inc. Copyright (C) 2010 PR Newswire. All rights reserved
  13. [verwijderd] 30 december 2010 20:15
    Na een mooie belegging in Crucell heb ik mijn aandelen verkocht.

    ik wou in m,n portefeuille toch een percentage aan pharmaceutische bedrijven hebben.

    en ja wat kies je dan???

    Ik heb gekozen voor AMT holding en Octoplus beide zijn met vernieuwende technieken bezig de een in Gentherapie en de ander met gecontroleerde afgifte van medicijnen in het lichaam.

    Freeliner

  14. forum rang 6 de tuinman 30 december 2010 22:06
    quote:

    Freeliner schreef op 30 december 2010 20:15:

    Na een mooie belegging in Crucell heb ik mijn aandelen verkocht.

    ik wou in m,n portefeuille toch een percentage aan pharmaceutische bedrijven hebben.

    en ja wat kies je dan???

    Ik heb gekozen voor AMT holding en Octoplus beide zijn met vernieuwende technieken bezig de een in Gentherapie en de ander met gecontroleerde afgifte van medicijnen in het lichaam.

    Freeliner

    En waarom niet galapagos?
  15. [verwijderd] 31 december 2010 10:48
    quote:

    de tuinman schreef:

    [...]

    En waarom niet galapagos?
    Het geld was op !!!!

    Ik denk dat Galapagos een hele goeie keuze is van u, omdat als Crucell daadwerkelijk wordt overgenomen dat het aandeelhouders belang in Galapagos door J&J erg groot word en daardoor een eventuele overname in de toekomst er misschien in zit.

    tevens succesbetalingen en breidt alliantie met Roche uit en de diverse samenwerkingen

    Gr Freeliner
  16. [verwijderd] 31 december 2010 19:46
    US HOT STOCKS: Imax, Universal American, Borders, Ensign Group
    Last update: 12/31/2010 1:20:17 PM

    PharmAthene Inc. (PIP, $4.17, +$0.18, +4.51%) gained as a trial on the biodefense company's breach of contract lawsuit against SIGA Technologies Inc. (SIGA, $13.95, -$0.01, -0.07%) is set to begin on Jan. 3. The case involves rights to a smallpox antiviral following a failed merger between the two companies.

    custom.marketwatch.com/custom/tdameri...
  18. [verwijderd] 3 januari 2011 19:06
    quote:

    jeroengp01 schreef op 3 januari 2011 18:56:

    Wat denken jullie van Patrys, in Australie? Nog klein, maar wellicht veelbelovende biotech. Ik hoor graag jullie commentaar. Zou mooi alternatief kunnen zijn om deel van je Crucell winst (if any) in te stoppen.
    Misschien leuk/zinvol om dan aan te geven waarom het een veelbelovend
    bedrijf zou kunnen zijn en een aantrekkelijk alternatief.Dit leidt dan van actie tot reactie en zodoende kan het (wellicht) een interessante discussie opleveren.
    Nu lijkt het meer of je een bevestiging zoekt zonder enige eigen inbreng.
  19. flosz 3 januari 2011 19:11
    Postje uit 2008 erbij:

    dedokter - 26 okt 08, 09:27
    Is gewoon een boevenbende. Publiek geld opmaken aan meer directeuren als overig personeel en naar de US sluizen als aankoop preferente aandelen. 12 cent per aandeel te veel
    *******************
    De laatste maanden is men overduidelijk(opvallend) de boel aan het opleuken om investeerders te lokken
    Organisatie van analistenbijeenkomsten, nieuwe website(up to date) , pb-machine van Crucell overgenomen (duo-gebruik met Gala,lol)

    Pers. steek ik er nog geen cent in, wel m'n neus, leuk om eens te kijken waar dit heen gaat.

    Veel mbt. Crucell/DSM en Patrys via:
    imode.iex.nl/forum/topic.asp?forum=22...

    Deze imode-link zal waarschijnlijk niet werken: even 1183243 in de verziek uh vernieuwde iex-site plakken.
  20. [verwijderd] 4 januari 2011 15:19
    De show begint, er zijn nog enkele kaarten te verkrijgen bij de kassa !

    Siga `Guaranteed' License on Smallpox Drug, Ex-PharmAthene Chief Testifies

    By Sophia Pearson and Jef Feeley - Jan 4, 2011 6:01 AM GMT+0100

    PharmAthene Inc.’s former chief executive officer testified Siga Technologies Inc. officials “guaranteed” it would get manufacturing rights to a drug designed to fight smallpox outbreaks linked to terrorist attacks.

    To spur merger talks between the two biotechnology companies, Siga’s then-Chairman Donald Drapkin vowed to grant PharmAthene a license to make the smallpox antiviral ST-246 and had terms of the agreement written out, ex-PharmAthene CEO David Wright said yesterday at a trial over the alleged accord.

    Drapkin “guaranteed it -- that we would either have a merger or a license to the product,” Wright testified in Delaware Chancery Court in Wilmington.

    PharmaAthene, based in Annapolis, Maryland, sued New York- based Siga in 2006, asking a judge to affirm the purported licensing agreement for the drug, which has grabbed the attention of U.S. officials seeking ways to counter potential biological attacks by terrorists. Siga contends that the licensing talks never concluded and that the written term sheet bore the heading “non-binding.”

    Siga said in October that the U.S. Health and Human Services Department selected it for a $500 million contract to produce 1.7 million doses of its smallpox antiviral. The contract may generate as much as $2.8 billion, according to court filings. Federal officials are investigating whether Siga qualifies for the contract.

    ‘Wouldn’t Back Out’

    In a January 2006 meeting, Drapkin sought “assurance from the PharmAthene board that the company wanted to do a merger and wouldn’t back out,” Wright said. Wright said he reassured Drapkin, who at the time was also vice chairman of Ronald Perelman’s holding company, MacAndrews & Forbes Holdings Inc.

    MacAndrews & Forbes had invested $10 million in Siga and was the company’s largest shareholder when it began talks with PharmaAthene over a possible merger or license for the smallpox treatment, according to court papers.

    Drapkin, a former mergers-and-acquisitions lawyer with New York-based law firms Cravath, Swaine & Moore LLP and Skadden, Arps, Slate, Meagher & Flom LLP, joined MacAndrews & Forbes in 1987. Last year, he started Casablanca Capital, a private-equity firm.

    At a March 2006 meeting, Drapkin told PharmAthene executives he had secured enough Siga board votes to ensure approval of a merger, and guaranteed that the company would either grant the license or pursue a combination, Wright testified.

    No Bentley
    “This was also the meeting where he promised that, if we got the stock price over $5 together, he would buy me a Bentley convertible,” Wright recalled. “I never got that either.”

    Andre Bouchard, a lawyer representing Siga, denied in court filings that Drapkin “orally guaranteed PharmAthene a license.” The companies “agreed only to negotiate a potential collaboration,” Bouchard wrote.

    During cross-examination yesterday, Wright acknowledged that the “non-binding” heading was never removed from the term sheet during the more than six months of negotiations between the companies.

    “In hindsight, it was an error of omission,” Wright told Harold Weinberger, one of Siga’s lawyers. Wright also acknowledged that Siga officials paid off a $3 million loan that helped fund the smallpox drug’s development.

    ‘Got The Product’

    Eric Richman, PharmAthene’s CEO and president, said the loan was tied to the prospect of a merger or a licensing deal.

    “We weren’t loaning another company money unless we merged or got the product,” Richman testified yesterday.

    Richman noted that he was the one who put the “non- binding” heading on documents outlining the terms of the licensing agreement.

    “I always put that on documents I sent outside the company,” he explained.

    Both biotech firms develop products to counter biological warfare agents, such as smallpox and anthrax. PharmAthene had a net loss of $32.3 million on 2009 sales of $27.6 million. Siga posted a net loss of $17.6 million on revenue of $13.8 million.

    Since its founding, PharmAthene has won at least $550 million in U.S. Government contracts and funding, according to its Website.

    PharmAthene rose 4 cents, or 1 percent, to $4.27 in NYSE Amex trading yesterday. Siga fell 44 cents, or 3.1 percent, to $13.56 in Nasdaq Stock Market trading yesterday.

    The case is PharmAthene Inc. v. Siga Technologies Inc., CA2627, Delaware Chancery Court (Wilmington).

    To contact the reporters on this story: Sophia Pearson in Wilmington, Delaware, at spearson3@bloomberg.net; Jef Feeley in Wilmington, Delaware, at jfeeley@bloomberg.net.

    To contact the editor responsible for this story: David E. Rovella at drovella@bloomberg.net.
    .
235 Posts
Pagina: «« 1 ... 6 7 8 9 10 ... 12 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 901,68 -0,38%
EUR/USD 1,0883 +0,03%
FTSE 100 8.232,04 -0,37%
Germany40^ 18.460,60 +0,30%
Gold spot 2.329,95 +0,13%
NY-Nasdaq Composite 16.857,05 +0,17%

Stijgers

Lotus ...
+2,30%
Elia
+2,21%
Care P...
+2,00%
Proximus
+1,64%
SHURGARD
+1,35%

Dalers

Recticel
-6,09%
Barco
-3,02%
Kinepolis
-2,79%
AZELIS...
-2,52%
Umicore
-2,14%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!